VYTRUS BIOTECH EO -01 (V5P) - Total Assets
Based on the latest financial reports, VYTRUS BIOTECH EO -01 (V5P) holds total assets worth €14.66 Million EUR (≈ $17.14 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
VYTRUS BIOTECH EO -01 - Total Assets Trend (2021–2025)
This chart illustrates how VYTRUS BIOTECH EO -01's total assets have evolved over time, based on quarterly financial data. Also see VYTRUS BIOTECH EO -01 (V5P) total market value for the company's overall valuation and market capitalisation.
VYTRUS BIOTECH EO -01 - Asset Composition Analysis
Current Asset Composition (December 2025)
VYTRUS BIOTECH EO -01's total assets of €14.66 Million consist of 36.8% current assets and 63.2% non-current assets. Review V5P liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.0% |
| Accounts Receivable | €982.01K | 6.7% |
| Inventory | €623.02K | 4.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.96 Million | 33.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how VYTRUS BIOTECH EO -01's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See VYTRUS BIOTECH EO -01 stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VYTRUS BIOTECH EO -01's current assets represent 36.8% of total assets in 2025, an increase from 25.3% in 2021.
- Cash Position: Cash and equivalents constituted 23.0% of total assets in 2025, up from 17.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, a decrease from 39.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 33.8% of total assets.
VYTRUS BIOTECH EO -01 Competitors by Total Assets
Key competitors of VYTRUS BIOTECH EO -01 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $4.32 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
VYTRUS BIOTECH EO -01 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 3.03 | 3.28 |
| Quick Ratio | 2.68 | 2.61 | 2.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.61 Million | €2.54 Million | €2.46 Million |
VYTRUS BIOTECH EO -01 - Advanced Valuation Insights
This section examines the relationship between VYTRUS BIOTECH EO -01's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.47 |
| Latest Market Cap to Assets Ratio | 8.77 |
| Asset Growth Rate (YoY) | 31.7% |
| Total Assets | €14.66 Million |
| Market Capitalization | $128.53 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values VYTRUS BIOTECH EO -01's assets at a significant premium (8.77x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: VYTRUS BIOTECH EO -01's assets grew by 31.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for VYTRUS BIOTECH EO -01 (2021–2025)
The table below shows the annual total assets of VYTRUS BIOTECH EO -01 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €14.66 Million ≈ $17.14 Million |
+31.72% |
| 2024-12-31 | €11.13 Million ≈ $13.01 Million |
+19.50% |
| 2023-12-31 | €9.31 Million ≈ $10.89 Million |
+16.38% |
| 2022-12-31 | €8.00 Million ≈ $9.36 Million |
+11.43% |
| 2021-12-31 | €7.18 Million ≈ $8.40 Million |
-- |
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more